- Home
- IOBT vs ANL Comparison
IOBT vs ANL Comparison
Compare IOBT & ANL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | IOBT | ANL |
|---|---|---|
| Founded | 2014 | 2004 |
| Country | Denmark | Cayman Islands |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 57.2M | 52.0M |
| IPO Year | 2021 | 2023 |
Fundamental Metrics
Financial Performance| Metric | IOBT | ANL |
|---|---|---|
| Price | $0.69 | $1.62 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 4 | 1 |
| Target Price | ★ $3.50 | N/A |
| AVG Volume (30 Days) | ★ 843.3K | 28.5K |
| Earning Date | 11-14-2025 | 04-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.32 | $0.88 |
| 52 Week High | $2.79 | $2.99 |
Technical Indicators
Market Signals| Indicator | IOBT | ANL |
|---|---|---|
| Relative Strength Index (RSI) | 43.67 | 60.74 |
| Support Level | $0.66 | $0.88 |
| Resistance Level | $0.88 | $1.59 |
| Average True Range (ATR) | 0.08 | 0.18 |
| MACD | 0.01 | 0.04 |
| Stochastic Oscillator | 35.14 | 91.60 |
Price Performance
Historical ComparisonAbout IOBT IO Biotech Inc.
IO Biotech Inc is a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on T-win technology platform. The product candidates are designed to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced immunosuppression.
About ANL Adlai Nortye Ltd.
Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.